Primer on Medical Genomics Part I: History of Genetics and Sequencing of the Human Genome

2002 ◽  
Vol 77 (8) ◽  
pp. 773-782 ◽  
Author(s):  
Cindy Pham Lorentz ◽  
Eric D. Wieben ◽  
Ayalew Tefferi ◽  
David A.H. Whiteman ◽  
Gordon W. Dewald
2011 ◽  
Vol 39 (1) ◽  
pp. 79-90 ◽  
Author(s):  
Britt M. Rusert ◽  
Charmaine D. M. Royal

Since the first phase of the formal effort to sequence the human genome, geneticists, social scientists and other scholars of race and ethnicity have warned that new genetic technologies and knowledge could have negative social effects, from biologizing racial and ethnic categories to the emergence of dangerous forms of genetic discrimination. Early on in the Human Genome Project (HGP), population geneticists like Luigi Luca Cavalli-Sforza enthusiastically advocated for the collection of DNA samples from global indigenous populations in order to track the history of human ancestry, migration, and languages, while social scientists like Troy Duster insisted that the new genetics was in danger of ushering in insidious practices of eugenics. The Human Genome Diversity Project's 1991 proposal to archive human genetic variation around the world quickly came under intense scrutiny by indigenous peoples and advocacy groups who worried that such measures could exploit indigenous groups as research populations and even resurrect racist taxonomies from the nineteenth century.


Author(s):  
Samir Okasha

There is no satisfactory one-line answer to the question ‘what exactly is a gene?’. The reasons why a precise definition is elusive are particularly interesting, and raise a number of philosophical subtleties. ‘Genes’ delves briefly into the history of genetics in order to understand them. It first looks at the work of Gregor Mendel in the 1860s and then the era of classical genetics in the 1920s and 1930s. It then moves on to molecular genetics, which came to fruition in the 1950s. How does the gene of Mendelian or classical genetics relate to the gene of molecular genetics? This question has long occupied philosophers of biology.


Genes ◽  
2019 ◽  
Vol 10 (5) ◽  
pp. 352 ◽  
Author(s):  
Karen H. Miga

The central goal of medical genomics is to understand the inherited basis of sequence variation that underlies human physiology, evolution, and disease. Functional association studies currently ignore millions of bases that span each centromeric region and acrocentric short arm. These regions are enriched in long arrays of tandem repeats, or satellite DNAs, that are known to vary extensively in copy number and repeat structure in the human population. Satellite sequence variation in the human genome is often so large that it is detected cytogenetically, yet due to the lack of a reference assembly and informatics tools to measure this variability, contemporary high-resolution disease association studies are unable to detect causal variants in these regions. Nevertheless, recently uncovered associations between satellite DNA variation and human disease support that these regions present a substantial and biologically important fraction of human sequence variation. Therefore, there is a pressing and unmet need to detect and incorporate this uncharacterized sequence variation into broad studies of human evolution and medical genomics. Here I discuss the current knowledge of satellite DNA variation in the human genome, focusing on centromeric satellites and their potential implications for disease.


Isis ◽  
1966 ◽  
Vol 57 (2) ◽  
pp. 278-279
Author(s):  
Conway Zirkle

2013 ◽  
Vol 19 (4) ◽  
Author(s):  
Laura M. McNamee ◽  
Fred D Ledley

Human Genome Science (HGS) aspired to dominate the emergent field of genomics by discovering expressed gene sequences and developing therapeutic and diagnostic products based on proprietary genes. While HGS’ accomplishments fell short of their own lofty expectations, by the time HGS was acquired by GlaxoSmithKline, the company had extensive intellectual property and had launched a product with >$1 billion market potential. Nevertheless, HGS’ acquisition price was less than the total capital investments in the company. This work examines HGS’ history and accomplishments in the context of the business plan described by the company at their IPO. We focus specifically on the company’s valuation over time, which was highly correlated with general market indices, but negatively correlated with metrics of technical or clinical progress. The history of HGS points to the challenge of accounting for the value created by a science-based business plan. Earnings-based metrics, present value calculations, and “fair value” assessments did not account for HGS’ progress in executing their stated business plan. This work highlights the critical need for accounting practices that credit value to the progress of translational science and enable investors to profit from such investments.


JAMA ◽  
1966 ◽  
Vol 197 (8) ◽  
pp. 667
Author(s):  
James E. Bowman

Sign in / Sign up

Export Citation Format

Share Document